CURRENT SERIES:
Oncology Stakeholders Summit, Spring 2015
April 22, 2015
April 22, 2015
April 22, 2015
NOW PLAYING
Incorporating Patient-Reported Outcomes in Drug Labels
4 of 25
May 06, 2015
May 20, 2015
May 27, 2015
May 27, 2015
May 27, 2015
May 27, 2015
June 04, 2015
June 04, 2015
June 11, 2015
June 11, 2015
June 25, 2015
June 25, 2015
June 25, 2015
June 25, 2015
July 06, 2015
July 06, 2015
July 07, 2015
July 07, 2015
July 14, 2015
July 14, 2015
July 14, 2015

Incorporating Patient-Reported Outcomes in Drug Labels

During this segment of the Oncology Stakeholders Summit, Spring 2015 series, the experts discuss their concerns and the concerns of manufacturers regarding the inclusion of patient-reported outcomes information in drug labels like the FDA's role in allowing the inclusion of PRO data, for example.


During this segment of the Oncology Stakeholders Summit, Spring 2015 series, Bruce Feinberg, DO; Scott Gottlieb, MD; and Michael Kolodziej, MD, discuss their concerns and the concerns of manufacturers regarding the inclusion of information on patient-reported outcomes (PROs) in drug labels.

Dr Gottlieb discusses the FDA’s role in allowing the inclusion of PRO data, notes the cumbersome process that manufacturers are faced with when incorporating the data into drug labels, and describes his concerns regarding how PRO data may be interpreted or misinterpreted by patients. For instance, he explains that in the oncology setting, where data regarding a drug’s efficacy are often the focus, if data on PROs are included in a drug label, patients may focus instead on quality-of-life claims. He adds that patients often make trade-offs based on side effect profiles.

Dr Kolodziej remarks that the costs of drugs further complicate the treatment decision-making process, especially in cancer recurrence scenarios. “I would want to know whether [the drug] works and what it is going to cost me,” says Dr Kolodziej, who is hopeful that PROs data will help to better define the true costs of healthcare.

Because patients will use the information found on drug labels when making personalized treatment decisions, Dr Kolodziej emphasizes the importance of considering PRO data as part of shared decision making.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up